ArticlemBio2017
A Variant PfCRT Isoform Can Contribute to
Open access · goldAbstract read
In one paragraph
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
15.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review.Malaria journal · 2022Pooled it
- African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker.Malaria journal · 2019Trial
- A Multidimensional Analysis of the Bimodal Piperaquine Response inbioRxiv : the preprint server for biology · 2026Article
- Article
- Heme processing in the malaria parasite, Plasmodium falciparum: a time-dependent basal-level analysis.Communications biology · 2025Article
- RecurrentmedRxiv : the preprint server for health sciences · 2025Article
- Review
- The plasmepsin-piperaquine paradox persists in Plasmodium falciparum.PLoS pathogens · 2025Article
- Plasmodium falciparum African PfCRT Mutant Isoforms Conducive to Piperaquine Resistance Are Infrequent and Impart a Major Fitness Cost.The Journal of infectious diseases · 2025Article
- Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.Parasites, hosts and diseases · 2025Review
- Deletion of theAntimicrobial agents and chemotherapy · 2025Article
- Unravelling the mode of action of the Tres Cantos Antimalarial Set (TCAMS): investigating the mechanism of potent antimalarial compounds potentially targeting the human serotonin receptor.Malaria journal · 2025Article
- Exploring Genetic Silencing: RNAi and CRISPR-Cas Potential against Drug Resistance in Malaria.Mini reviews in medicinal chemistry · 2025Review
- Dihydroartemisinin-Piperaquine Combination in the Treatment of UncomplicatedJournal of clinical medicine · 2024Review
- Recent Advances in the Treatment of Malaria.Pharmaceutics · 2024Review
- AmBio · 2024Article
- Article
- IncompleteFrontiers in cellular and infection microbiology · 2024Article
- Mapping the genomic landscape of multidrug resistance inScience advances · 2023Article
- Critical interdependencies between Plasmodium nutrient flux and drugs.Trends in parasitology · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Satish K DhingraDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
Devasha RedhiDivision of Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Jill M CombrinckDivision of Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Tomas YeoDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
John OkomboDepartment of Chemistry, University of Cape Town, Cape Town, South Africa.
Philipp P HenrichDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
Annie N CowellDivision of Infectious Diseases, Department of Internal Medicine, University of California, San Diego, California, USA.
Purva GuptaDivision of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California, San Diego, California, USA.
Matthew L StegmanDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USA.
Jonathan M HokeDepartment of Biological Sciences, Old Dominion University, Norfolk, Virginia, USA.
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USA.
Elizabeth WinzelerDivision of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California, San Diego, California, USA.
Sachel MokDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
Timothy J EganDepartment of Chemistry, University of Cape Town, Cape Town, South Africa.
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA df2260@cumc.columbia.edu.ORCID 0000-0001-6753-8938
Columbia University Irving Medical Center · USUniversity of Cape Town · ZAUniversity of California San Diego · USDominican University of California · USOld Dominion University · US
Funding
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2MRole of pfcrt in chloroquine resistance in P. falciparumR01AI050234 · NIAID · YESHIVA UNIVERSITY · PI FIDOCK, DAVID A · 2001 to 2015
$5.7MDefining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4MElucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3MDefining the targets of broad intervention antimalarial agentsR01AI103058 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2013 to 2016
$2.6MDeterminants of growth and fitness in drug resistant malaria parasitesR01AI071121 · NIAID · UNIVERSITY OF NOTRE DAME · PI FERDIG, MICHAEL T · 2008 to 2012
$1.8MPlasmodium heme detoxification probesR01AI110329 · NIAID · UNIVERSITY OF CAPE TOWN · PI EGAN, TIMOTHY JOHN · 2014 to 2018
$668kNIAID NIH HHS R01 AI050234NIAID NIH HHS R01 AI071121NIAID NIH HHS R01 AI103058NIAID NIH HHS R01 AI110329NIAID NIH HHS R01 AI124678NIAID NIH HHS R37 AI050234NIAID NIH HHS T32 AI007036
Abstract
Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of
Indexed as
AntimalarialsArtemisininsATP-Binding Cassette, Sub-Family C ProteinsCambodiaDrug ResistanceGene EditingHumansLethal Dose 50Malaria, FalciparumMembrane Transport ProteinsMutationPiperazinesPlasmodium falciparumProtein IsoformsProtozoan ProteinsQuinolinesAntimalarialsartemisininArtemisininsartenimolATP-Binding Cassette, Sub-Family C ProteinsHDP protein, Plasmodium falciparumMdr1 protein, Plasmodium falciparumMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumpiperaquinePiperazinesProtein IsoformsProtozoan ProteinsQuinolinesartemisinin-based combination therapiesdigestive vacuolegenome editingheme detoxificationmalariaPfCRTpiperaquine resistancePlasmodium falciparum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.